Explore Cell Therapy
In Explore Cell Therapy, we dig into the latest cell and gene therapy research and best practices to help you advance care for patients with hematologic malignancies and disorders. You’ll hear interviews with well-known and up-and-coming physicians in the hematopoietic stem cell transplantation (HCT) and cell and gene therapy field. You’ll receive insights from the National Marrow Donor Program®/Be The Match® and our partners into what it takes to connect patients to the best available therapies. In season 2, we examine practice-changing research and hot topics in HCT and other cellular therapies. You’ll hear conversations with experts who specialize in HCT and at community hematology/oncology practices.
Listen on:
Episodes
Tuesday Feb 28, 2023
Tuesday Feb 28, 2023
In this two-part episode, Stephen Spellman, MBS, and Jeffrey Auletta, MD, with the National Marrow Donor Program®/Be The Match® and the CIBMTR® (Center for International Blood and Marrow Transplantation Research) discuss the current state of the science in finding an optimal donor for all patients in need of allogeneic hematopoietic cell transplantation.
In Part II: Donor Optimization and Looking into the Future, experts share the opportunity to close equity gaps, optimize donor selection, and further expand access to transplant.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Monday Feb 13, 2023
Monday Feb 13, 2023
In this two-part episode, Stephen Spellman, MBS, and Jeffrey Auletta, MD, with the National Marrow Donor Program®/Be The Match® and the CIBMTR® (Center for International Blood and Marrow Transplantation Research) discuss the current state of the science in finding an optimal donor for all patients in need of allogeneic hematopoietic cell transplantation.
In Part I: Donor Availability and Addressing Barriers, experts explore advances that have improved donor availability and how barriers can be addressed for patients in need of transplant.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Tuesday Dec 06, 2022
Tuesday Dec 06, 2022
In this two-part episode, Irum Khan, MD, of University of Illinois Chicago and Jonathan Moreira, MD, of Northwestern University explore novel research on the impact of structural racism on acute myeloid leukemia (AML) outcomes for underserved communities and ethnically diverse patients in the Chicago area. In Part II: Addressing Barriers and Equity Across Healthcare Teams, guests examine solutions to improve access and address barriers to care, emphasizing policy reform and the importance of strong provider relationships across the patient’s transplant journey. For more information, research and resources from this episode, or full bios of our guests, visit our site.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Monday Nov 28, 2022
Monday Nov 28, 2022
In this two-part episode, Irum Khan, MD, of University of Illinois Chicago and Jonathan Moreira, MD, of Northwestern University explore novel research on the impact of structural racism on acute myeloid leukemia (AML) outcomes for underserved communities and ethnically diverse patients in the Chicago area. In Part I: The Impact of Structural Racism on AML Outcomes, Dr. Khan shares findings from her eye-opening research and examines implications on health disparities and barriers to care for ethnically diverse patients through discussion with Dr. Moreira. For more information, research and resources from this episode, or full bios of our guests, visit our site.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Tuesday Oct 11, 2022
Tuesday Oct 11, 2022
In part two of this episode, Kelley Steffens, Dr. Woods, and Dr. Stefanski dig deeper into barriers to care and health equity concerns for adult and pediatric patients in need of HCT. They go on to discuss how building relationships, connectivity, and shared care between hematology/oncology practices and transplant centers can help, and ways to apply these principles to clinical practice.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Tuesday Sep 27, 2022
Tuesday Sep 27, 2022
In a two-part episode on Evidence for Shared Care in HCT, our expert guests discuss recent research supporting strong relationships between hematology/oncology and transplant center care teams. Wendy Woods (formally Woods-Swafford), MD, MPH of Blank Children’s Hospital, and Heather Stefanski, MD, PhD of the National Marrow Donor Program® (NMDP)/Be The Match®, join Kelley Steffens, principal investigator and research manager at NMDP/Be The Match, to examine research findings and discuss best practices for shared or coordinated care to address access, barriers to care, and equity concerns in HCT.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Tuesday Jul 12, 2022
Tuesday Jul 12, 2022
In this two-part episode, Karen Ballen, MD, of University of Virginia Health, and Mitul Gandhi, MD, of Virginia Cancer Specialists discuss recent research around access to HCT, as well as overcoming HCT barriers through coordinated care between transplant centers and hematology/oncology practices. In Part II: Health Equity, Solutions and Building Trust via Shared Care, they examine health disparities in access for ethnically diverse patients, propose solutions to overcome barriers for all in need of HCT, and stress the importance of shared and coordinated care between providers on the path to transplant.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Thursday Jun 30, 2022
Thursday Jun 30, 2022
In this two-part episode, Karen Ballen, MD, of University of Virginia Health, and Mitul Gandhi, MD, of Virginia Cancer Specialists discuss recent research around access to HCT, as well as overcoming HCT barriers through coordinated care between transplant centers and hematology/oncology practices. In Part I: Barriers in HCT and the Importance of Time, they discuss major findings from Dr. Ballen’s recent research and explore the importance of early consultation to give patients, caregivers, and providers more time to ensure optimal outcomes.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.
Thursday May 12, 2022
Thursday May 12, 2022
This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part 3: Persistent Misconceptions, Coordinated Care and the Future of HCT, they discuss the challenge and importance of understanding when, who, and how to refer for a transplant consultation, promoting coordinated care and open communication across the care team. They also discuss emerging advances and the future of HCT, including CAR-T and treatments for sickle cell and thalassemia. For more information, resources from the episode, or full bios of our guests, visit our site.
Thursday May 05, 2022
Thursday May 05, 2022
This three-part episode follows a discussion of the current state of HCT by exploring its evolution over time. Fred Appelbaum, MD, of Fred Hutchinson Cancer Center, and Courtney Bellomo, MD, of New York Oncology Hematology lead the discussion. In Part 2: Donor Availability, Graft Sources and the Birth of NMDP, they discuss how unrelated donor availability and alternative stem cell sources have substantially increased access to HCT. They share the story of the first unrelated donor transplant for leukemia, performed at Fred Hutch in 1979, and how it led to the development of the NMDP/Be The Match Registry.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.